NICE Rejects Bayer’s Nexavar as Liver Cancer Treatment

8 September 2009 (Last Updated September 8th, 2009 18:30)

Bayer's liver cancer drug Nexavar (sorafenib) has been rejected by the UK's National Institute of Health and Clinical Excellence (NICE) for it to be given to patients free on the National Health Service (NHS). Bayer and its partner Onyx Pharmaceuticals have previously had Nexavar turne

Bayer's liver cancer drug Nexavar (sorafenib) has been rejected by the UK's National Institute of Health and Clinical Excellence (NICE) for it to be given to patients free on the National Health Service (NHS).

Bayer and its partner Onyx Pharmaceuticals have previously had Nexavar turned down by the cost-effectiveness watchdog to treat kidney cancer, Reuters reports.

Bayer had revised its charging scheme after NICE indicated it would not be provided for hepatocellular carcinoma patients on the NHS in May, the news service said.